Inhibitory Effect of Metformin Therapy on the Incidence of Colorectal Advanced Adenomas in Patients With Diabetes.
- Author:
Yo Han KIM
1
;
Ran NOH
;
Sun Young CHO
;
Seong Jun PARK
;
Soung Min JEON
;
Hyun Deok SHIN
;
Suk Bae KIM
;
Jeong Eun SHIN
Author Information
- Publication Type:Original Article
- Keywords: Advanced colorectal adenoma; Diabetes mellitus; Incidence; Metformin
- MeSH: Adenoma*; Colonoscopy; Colorectal Neoplasms; Demography; Diabetes Mellitus; Follow-Up Studies; Humans; Incidence*; Metformin*; Mortality; Retrospective Studies
- From:Intestinal Research 2015;13(2):145-152
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Metformin use has been associated with decreased colorectal cancer risk and mortality among diabetic patients. Recent research suggests that metformin use may decrease the incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. This study aimed to assess the clinical effect of metformin use on the development of colorectal adenomas in diabetic patients without previous colorectal cancer. METHODS: Among 604 consecutive diabetic patients who underwent colonoscopic surveillance after initial colonoscopy between January 2002 and June 2012, 240 patients without previous colorectal cancer were enrolled in this study and were divided in two groups: 151 patients receiving metformin and 89 patients not receiving metformin. Patient demographics and clinical characteristics as well as the colorectal adenoma incidence rate were retrospectively analyzed. RESULTS: The incidence rate of total colorectal adenomas was not different according to metformin use (P=0.349). However, the advanced adenoma incidence rate was significantly lower in the metformin group compared with the non-metformin group (relative risk [RR], 0.09; P=0.011). Metformin use was independently associated with a decreased incidence of advanced colorectal adenomas after adjustment for clinically relevant factors (RR, 0.072; P=0.016). In addition, the cumulative development rate of advanced adenomas during follow-up was significantly lower in the metformin group compared with the non-metformin group (P=0.007). CONCLUSIONS: Metformin use in diabetic patients without previous colorectal cancer is associated with a lower risk of advanced colorectal adenomas.
